Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
29 hedge funds and large institutions have $961M invested in Sinovac Biotech, Ltd in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
625% more funds holding
Funds holding: 4 → 29 (+25)
0% more capital invested
Capital invested by funds: $957M → $961M (+$3.54M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.54M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 3 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
+$291K |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$259K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$179K |
Top Sellers
SVA Hedge Fund Activity: Q2 2023 in Review
29 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2023, worth a combined $961M — up 0.37% from $957M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SVA positions and 0 closed out — a net gain of 25 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.54M.
- 29 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2023, up from 4 in Q1 2023.
- Funds reported $961M of Sinovac Biotech, Ltd stock for Q2 2023, up 0.37% quarter-over-quarter.
- 25 funds opened new Sinovac Biotech, Ltd positions in Q2 2023 and 0 closed out, a net change of +25 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2023 was Renaissance Technologies, an estimated $1.54M added.
Based on aggregated 13F filings for Q2 2023.